DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NIASPAN

Summary for Tradename: NIASPAN

Patents:9
Applicants:1
NDAs:1
Suppliers: see list7
drug
patent expirations by year for
 NIASPAN

Pharmacology for Tradename: NIASPAN

Ingredient-typeNicotinic Acids
Drug ClassNicotinic Acid

Clinical Trials for: NIASPAN

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)(COMPLETED)
Status: Completed Condition: Hypercholesterolemia; Hyperlipidemia

Biosynthesis of PGD2 in Vivo
Status: Completed Condition: Healthy Volunteer

Niacin on Immune Activation : a Proof-of-concept Study
Status: Recruiting Condition: HIV

Randomized, Controlled Trial of Extended-Release Niacin (NiaspanĀ®) to Augment Subacute Ischemic Stroke Recovery
Status: Completed Condition: Ischemic Stroke

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
Status: Completed Condition: Healthy Volunteers

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Status: Completed Condition: Healthy

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on NiaspanĀ®-Induced Flushing in Subjects With Dyslipidemia
Status: Completed Condition: Dyslipidemia

Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Status: Active, not recruiting Condition: Elevated Lipoprotein(a) Levels

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Status: Completed Condition: Hypercholesterolemia

Short-term Effect of Extended-release Niacin on Endothelial Function.
Status: Completed Condition: Hypoalphalipoproteinemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997DISCNNo6,080,428<disabled><disabled>
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997DISCNNo6,129,930<disabled><disabled>
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997DISCNNo6,406,715<disabled><disabled>
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997DISCNNo6,746,691<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc